Lilly and the Fever said they would also use the partnership “to close gaps on health outcomes in Indianapolis and across the state” by raising awareness of health issues.
As Novo and Lilly fight to dominate the market in weight-loss drugs, gaining an edge in manufacturing power is emerging as a new front. Both drugmakers are racing to secure the highly specialized plants that can churn out enough of their top-selling drugs to keep up with demand.
The drugmaker accused 11 companies of importing products that they say contain tirzepatide, the active ingredient in Mounjaro, while falsely implying that their products are associated with Eli Lilly or approved by the FDA.
Lilly is suing medical spas, wellness centers and compounding pharmacies in various U.S. states that sell unapproved versions of its blockbuster diabetes drug, which is frequently used off-label for weight loss.
The Biden administration is targeting diabetes treatment Jardiance and nine other medications for Medicare’s first-ever drug price negotiations as it seeks to lower medical costs for Americans.
The Indianapolis-based drugmaker said it will acquire Sigilon Therapeutics Inc., a six-year-old startup that is developing a technology to help type 1 diabetes patients restore insulin production over sustained periods.
The Lebanon Plan Commission voted unanimously Monday to approve Eli Lilly and Co.’s development plan for its two manufacturing facilities in Boone County.
The Weinberg Center for Corporate Governance at the University of Delaware, a leading voice for responsible corporate leadership, has generally supported the elimination of staggered terms, saying they can lead to entrenched boards and management that fails to perform.
The Indianapolis-based drugmaker released a report card Thursday that outlined its progress “to support effective solutions” to racial inequity and social injustice. In addition to donations, the company has committed tens of millions of dollars to other diversity efforts.
By Friday morning, Eli Lilly executives had ordered a halt to all Twitter ad campaigns—a potentially serious blow, given that the $330 billion company controls the kind of massive advertising budget that Musk says the company needs to avoid bankruptcy.
The stock sale is a primary way for the endowment, one of the largest private philanthropic foundations in the United States, to raise cash to make grants to arts, education, religious and community development organizations.
Additionally, the pharmaceutical giant said in a statement that it had “suspended all investments, promotional activities, and new clinical trials in Russia.”
The FDA has agreed to speed up review of donanemab, but the Centers for Medicare and Medicaid Services is moving to limit reimbursement for drugs in this class to only patients in clinical trials.
Indianapolis-based Eli Lilly and Co., one of three primary U.S. insulin manufacturers, said it was “deeply disappointed by the false accusations and inaccurate claims” made by the attorney general.
Indianapolis-based Eli Lilly and Co. will make an initial $50 million payment to Entos Pharmaceuticals. Entos also could receive up to $400 million in potential milestone payments, as well as royalties, for successful products.
Lilly’s BLAZE-1 study examined antibody therapy engineered from one of the first individuals in the United States to recover from COVID and was specifically designed to attack the virus that causes it, SARS-CoV-2.
